All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

ELOQUENT-2 trial to assess efficacy of elotuzumab therapy for RRMM

Mar 1, 2017

Bookmark this article

In August 2015, Sagar Lonial, Meletios D. Dimopoulos and colleagues, reported results from the open-label, multi-center ELOQUENT-2 trial in The New England Journal of Medicine. This was the pivotal phase III study leading to approval of elotuzumab for the treatment of patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). They enrolled 646 patients (between June 2011 and November 2012 at 168 sites globally) who had received one to three prior therapies, and who had relapsed following their most recent therapy. Patients were randomly assigned into two treatment groups, receiving a combined regimen of lenalidomide plus dexamethasone plus elotuzumab (321 patients) or lenalidomide plus dexamethasone alone (control, 325 patients). Primary endpoints were Progression Free Survival (PFS) and Overall Response Rate (ORR).


  • Treatment was administered in 28-day cycles
  • Intravenous elotuzumab (10 mg/kg of body weight) was administered on days 1, 8, 15 and 22, during cycle 1 and 2, then on day 1 and 15 in cycle 3
  • Oral lenalidomide (25 mg per day) was administered from day 1 –day 21 of each cycle
  • Oral dexamethasone (40 mg) was administered during the week without elotuzumab and intravenously at a dose of 8 mg, plus 28 mg orally on the day of elotuzumab treatment (days 1, 8, 15 and 21)
  • Control group received the same regimen, minus elotuzumab
  • Pre-medication (H1 blocker, H2 blocker, and acetaminophen) were administered prior to elotuzumab infusion
  • Only 10% of patients that received previous lenalidomide treatment were allowed to enrol

Key Findings:

Data is given as elotuzumab vs control:

  • Median follow-up = 24.5 months
  • Pts still receiving treatment at the cut-off date for interim analysis = 35% vs 20%
  • Rate of PFS: 1 year: 68% vs 57%; 2 years: 41% vs 27%
  • Median PFS: 19.4 months (95% CI, 16.6 to 22.2) vs 14.9 months (95% CI, 12.1 to 17.2)
  • HR = 0.70; 95% CI, 0.57 to 0.85; P<0.001
  • Safety dataset: elotuzumab = 318 pts and control = 317 pts
  • ITT population: 32% relative reduction in the risk of disease progression in the elotuzumab group (HR, 0.68; 95% CI, 0.56-0.83)
  • ORR: 79% (95% CI, 74-83) vs 66% (95% CI, 60-71) (odds ratio for elotuzumab vs control = 1.9 (95% CI, 0.44 to 0.70); P<0.001)
  • Durable responses: 21 months (95% CI, 18 to 27) vs 17 months (95% CI, 15 to 19)
  • Grade 3 or 4 AEs were: lymphocytopenia, neutropenia, fatigue, and pneumonia
  • Infusion reactions in elotuzumab group = 33 pts (10%); grade 1 or 2 in 29 patients
  • Pts continued treatment until the development of unacceptable toxicity or due to disease progression

Patients receiving elotuzumab, on a background of the combined regimen of lenalidomide plus dexamethasone, had a 30% reduction in the risk of disease progression or death. This trial was pivotal in driving the approval of elotuzumab by the US Food and Drug Administration (US FDA) (in November 2015) for use in combination with two other therapies, to treat patients with MM who have received one to three prior medications. Elotuzumab was also approved by the European Medicines Agency (EMA) (in January 2016) for the same indication. The full article can be found here.


  1. Lonial S, Dimopoulos M. et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.N Engl J Med. 2015 Aug 13;373(7):621-31. DOI: 10.1056/NEJMoa1505654.

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
14 votes - 17 days left ...


Subscribe to get the best content related to multiple myeloma delivered to your inbox